Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”

A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadigal, Sanjay, Colombo, Laura, Haughie, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Influenza – Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624209/
https://www.ncbi.nlm.nih.gov/pubmed/35674507
http://dx.doi.org/10.1080/21645515.2022.2085470
_version_ 1784822183184302080
author Hadigal, Sanjay
Colombo, Laura
Haughie, Scott
author_facet Hadigal, Sanjay
Colombo, Laura
Haughie, Scott
author_sort Hadigal, Sanjay
collection PubMed
description A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV) is an important tool to measure the benefit of a given vaccine. Further, NNV evaluates the benefits of a vaccine in preventing and controlling communicable diseases. Considering the target of vaccination and coverage of 75% not met in the elderly in Europe, it is important not to prioritize one vaccine over the other, but rather to increase the vaccine coverage with all the available vaccines.
format Online
Article
Text
id pubmed-9624209
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-96242092022-11-02 Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial” Hadigal, Sanjay Colombo, Laura Haughie, Scott Hum Vaccin Immunother Influenza – Letters A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV) is an important tool to measure the benefit of a given vaccine. Further, NNV evaluates the benefits of a vaccine in preventing and controlling communicable diseases. Considering the target of vaccination and coverage of 75% not met in the elderly in Europe, it is important not to prioritize one vaccine over the other, but rather to increase the vaccine coverage with all the available vaccines. Taylor & Francis 2022-06-08 /pmc/articles/PMC9624209/ /pubmed/35674507 http://dx.doi.org/10.1080/21645515.2022.2085470 Text en © 2022 Viatris. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Influenza – Letters
Hadigal, Sanjay
Colombo, Laura
Haughie, Scott
Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
title Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
title_full Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
title_fullStr Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
title_full_unstemmed Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
title_short Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
title_sort reply letter to “immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized phase iii trial”
topic Influenza – Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624209/
https://www.ncbi.nlm.nih.gov/pubmed/35674507
http://dx.doi.org/10.1080/21645515.2022.2085470
work_keys_str_mv AT hadigalsanjay replylettertoimmunogenicityandsafetyofaquadrivalenthighdoseinactivatedinfluenzavaccinecomparedwithastandarddosequadrivalentinfluenzavaccineinhealthypeopleaged60yearsorolderarandomizedphaseiiitrial
AT colombolaura replylettertoimmunogenicityandsafetyofaquadrivalenthighdoseinactivatedinfluenzavaccinecomparedwithastandarddosequadrivalentinfluenzavaccineinhealthypeopleaged60yearsorolderarandomizedphaseiiitrial
AT haughiescott replylettertoimmunogenicityandsafetyofaquadrivalenthighdoseinactivatedinfluenzavaccinecomparedwithastandarddosequadrivalentinfluenzavaccineinhealthypeopleaged60yearsorolderarandomizedphaseiiitrial

Ejemplares similares